RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Ultragenyx Pharmaceutical Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$15.07+0.53 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
Ultragenyx Pharmaceutical statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Market Cap | $1.49B | $166.30M |
| Enterprise Value | $1.19B | $88.19M |
| PS Ratio | 2.07 | 3.65 |
Enterprise value
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| EV / Sales | 1.66 | 2.51 |
Income (trailing twelve months)
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Revenue | $717.21M | $58.34M |
| Operating Income | -$528.17M | -$21.40M |
| Pretax Income | -$582.23M | -$14.34M |
| Net Income | -$585.97M | -$22.46M |
| EBITDA | -$495.17M | -$16.91M |
| EPS (Diluted) | -$5.84 | -$0.83 |
Margins
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Operating Margin | -73.6% | -44.0% |
| Pretax Margin | -81.2% | -13.3% |
| Profit Margin | -81.7% | -40.2% |
| EBITDA Margin | -69.0% | -30.2% |
| FCF Margin | -68.2% | -9.27% |
Returns
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Return on Assets (ROA) | -45.6% | -40.9% |
| Return on Capital Employed (ROCE) | -57.9% | -38.1% |
Growth
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 17.5% | 5.96% |
| Revenue Growth (3Y CAGR) | 22.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 19.9% | 6.48% |
Balance sheet
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $292.00M | $61.43M |
| Net Cash (Debt) | $292.00M | $15.35M |
| Net Cash Per Share | $2.96 | $0.66 |
| Equity (Book Value) | -$291.00M | $49.09M |
| Book Value Per Share | -$2.95 | $1.37 |
| Tangible Book Value | -$507.00M | $23.52M |
| Working Capital | $255.00M | $76.81M |
Financial position
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Current Ratio | 1.73 | 3.34 |
| Quick Ratio | 1.40 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Operating Cash Flow | -$485.00M | -$12.35M |
| Capital Expenditures | -$4.00M | -$1.08M |
| Free Cash Flow | -$489.00M | -$20.22M |
| FCF Per Share | -$4.96 | -$0.42 |
Efficiency
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Asset Turnover | 0.56 | 0.39 |
| Revenue Per Employee | $523.13K | $404.87K |
| Profits Per Employee | -$427.40K | -$703.34K |
| Employee Count | 1,371 | 74 |
Dividends and yields
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Earnings Yield | -39.4% | -23.3% |
| FCF Yield | -32.9% | -8.72% |
Shares
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Shares Outstanding | 98,588,900 | 58,127,000 |
| Shares Change (YoY) | 4.21% | 10.9% |
| Shares Change (QoQ) | 0.31% | 0.54% |
| Float | 94,628,300 | 49,136,700 |
| Shares Held by Insiders | 4.02% | 11.6% |
| Shares Held by Institutions | 108.4% | 59.4% |
Taxes
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Income Tax | $3.74M | $79.87K |
Scores
| Measure | Ultragenyx Pharmaceutical | Industry median |
|---|---|---|
| Altman Z-Score | -5.32 | -0.22 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Ultragenyx Pharmaceutical's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.